Clinical Trials Browser

INDUSTRY × Lennox Gastaut Syndrome × Clear all

Epilepsies, Myoclonic, Seizures, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT05044819 2026-06-01

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Phase 4 Active not recruiting

154 enrolled

Epilepsies, Myoclonic, Liver Cirrhosis, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT05626634 2025-12-03

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

Phase 2 Completed

41 enrolled

CDKL5 deficiency disorder, Epilepsy, Epilepsies, Myoclonic, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT04485104 2025-10-31

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Phase 3 Terminated

3 enrolled 28 charts

Tuberous Sclerosis 1, Tuberous Sclerosis 2, Epilepsy, Epilepsies, Myoclonic, Seizures, Spasms, Infantile, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT06149663 2025-01-22

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Available

CDKL5 deficiency disorder, Epilepsy, Epilepsies, Myoclonic, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT05364021 2024-11-08

PACIFIC

Phase 1/2 Completed

52 enrolled

CDKL5 deficiency disorder, Epilepsy, Epilepsies, Myoclonic, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT03650452 2021-02-18

ELEKTRA

Phase 2 Completed

141 enrolled 24 charts

CNS

CDKL5 deficiency disorder, Brain Diseases, Central Nervous System Diseases, Epilepsy, Epilepsies, Myoclonic, Nervous System Diseases, Seizures, Spasms, Infantile, Tuberous Sclerosis, Hypoxia-Ischemia, Brain, Malformations of Cortical Development, Lennox Gastaut Syndrome

Clinical Trials

EpiTALY

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Intermediate-Size Expanded Access Protocol (EAP) for LP352

PACIFIC

ELEKTRA